, Volume 9, Issue 1, pp 57–59 | Cite as

TSH suppressive therapy: An overview of long-term clinical consequences

  • David S. CooperEmail author


An overview of long-term clinical consequences of TSH suppressive therapy provides evidence that serum TSH levels should be maintained at levels <0.1 mU/l in high-risk (stage III and IV) patients, whereas lower-risk patients should be allowed to have their TSH levels rise into the normal range after residual disease has been ruled out by imaging and/or stimulated thyroglobulin measurement. The proper management of patients with known residual thyroid cancer, who are also elderly or who have underlying serious comorbidities (e.g., osteoporosis, cardiovascular disease, diabetes), is uncertain and requires a high degree of clinical experience and judgment.


Thyroid cancer TSH suppression Thyroxin therapy 


  1. 1.
    Dunhill TP, 1937 Surgery of the thyroid gland (The Lettsomian Lectures). BMJ 1: 460–461.CrossRefGoogle Scholar
  2. 2.
    Brabant G, 2008 Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 93: 1167–1169.CrossRefGoogle Scholar
  3. 3.
    Mazzaferri EL, Kloos RT, 2001 Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86: 1447–1463.CrossRefGoogle Scholar
  4. 4.
    Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C, 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81: 4318–4323.PubMedGoogle Scholar
  5. 5.
    Cooper DS, Specker B, Ho M, et al, 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8: 737–744.CrossRefGoogle Scholar
  6. 6.
    McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ, 2002 Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34: 554–564.CrossRefGoogle Scholar
  7. 7.
    Jonklaas J, Sarlis NJ, Litofsky D, et al, 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16: 1229–1242.CrossRefGoogle Scholar
  8. 8.
    Hovens GC, Stokkel MP, Kievit J, et al, 2007 Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 92: 2610–2615.CrossRefGoogle Scholar
  9. 9.
    Cooper DS, Doherty GM, Haugen BR, et al, The Revised American Thyroid Association Guidelines Taskforce, 2009 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167–1214.CrossRefGoogle Scholar
  10. 10.
    Pacini F, Schlumberger M, Dralle H, et al, European Thyroid Cancer Taskforce, 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154: 787–803.CrossRefGoogle Scholar
  11. 11.
    Biondi B, Cooper DS, 2008 The clinical significance of subclinical thyroid dysfunction Endocr Rev 29: 76–131.CrossRefGoogle Scholar
  12. 12.
    Biondi B, Filetti S, Schlumberger M, 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1: 32–40.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2010

Authors and Affiliations

  1. 1.Division of Endocrinology and MetabolismJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations